Systemische Therapie von Osteosarkomen. Wege aus der prognostischen Stagnation?

Bielack, Stefan S.; Reichardt, Peter; Lindner, Lars H. und Hecker-Nolting, Stefanie (2022): Systemische Therapie von Osteosarkomen. Wege aus der prognostischen Stagnation? In: Onkologie, Bd. 28, Nr. 7: S. 555-562

Abstract

Background Osteosarcomas are the most frequent primary bone malignancies. Standard treatment consists of complete surgical excision and a period of intensive pre- and postoperative chemotherapy. Objective Description of standard medical treatment and current developments regarding perspectives of drug-based cancer treatment that is based on the age of the patients. Materials and methods We performed a nonsystematic review of the literature. Results As mandated by epidemiology, most therapeutic trials were performed in children, adolescents, and young adults. However, recent decades have witnessed a stagnation in prognosis rates. Combining existing chemotherapeutic treatments with novel tyrosine kinase inhibitors may offer a strategy to end this stagnation. Studies demonstrating any benefit of this combination are, however, still pending. Adults of intermediate age also benefit from adding systemic to local therapies. The choice and doses of agents must be adapted to the age of the patient. Almost nothing is known about treating patients of retirement age, who often tolerate conventional systemic therapy poorly. Due to the lack of trials in this age group, individualized decisions have to be made. Conclusion It is hoped that the rapid gains in knowledge about tumor biology will also lead to therapeutic progress in osteosarcoma patients of all ages.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 2731-7226
• Sprache: Deutsch